References

Berzolla CE, Schnatz PF, O'Sullivan DM, Bansal R, Mandavilli S, Sorosky JI. Dysplasia and malignancy in endocervical polyps. J Womens Health (Larchmt). 2007; 16:(9)1317-1321 https://doi.org/10.1089/jwh.2007.0408

Bray F, Dos Santos Silva I, Moller H, Weiderpass E. Endometrial cancer incidence trends in Europe: underlying determinants and prospects for prevention. Cancer Epidemiol Biomarkers Prev. 2005; 14:(5)1132-1142 https://doi.org/10.1158/1055-9965.EPI-04-0871

Brinton LA, Lacey JV, Trimble EL. Hormones and endometrial cancer--new data from the Million Women Study. Lancet. 2005; 365:(9470)1517-1518 https://doi.org/10.1016/S0140-6736(05)66431-8

Costa-Paiva L, Godoy CE, Antunes A, Caseiro JD, Arthuso M, Pinto-Neto AM. Risk of malignancy in endometrial polyps in premenopausal and postmenopausal women according to clinicopathologic characteristics. Menopause. 2011; 18:(12)1278-1282 https://doi.org/10.1097/gme.0b013e31821e23a1

Gajjar Dave F, Adedipe T, Disu S, Laiyemo R. Unscheduled bleeding with hormone replacement therapy. The Obstetrician and Gynaecologist. 2019; 21:95-01 https://doi.org/10.1111/tog.12553

Hickey M, Ambekar M. Abnormal bleeding in postmenopausal hormone users—what do we know today?. Maturitas. 2009; 63:(1)45-50 https://doi.org/10.1016/j.maturitas.2009.03.010

Hillard T, Abernethy K, Hamoda H, Shaw I, Everett M, Ayres J, Currie H. Management of the menopause, 6th edn. London: Royal Society of Medicine Press; 2017

NHS. NHS Cancer Plan. 2000. https://www.thh.nhs.uk/documents/_Departments/Cancer/NHSCancerPlan.pdf (accessed 11 November 2020)

Rossouw JE, Anderson GL, Prentice RL Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002; 288:(3)321-333 https://doi.org/10.1001/jama.288.3.321

Investigation of post-menopausal bleeding: A national clinical guideline. SIGN publication no 61. 2002;

Management of bleeding in women on HRT

02 December 2020
9 min read
Volume 31 · Issue 12

Abstract

Bleeding while on hormone replacement therapy is common. Debby Holloway explains the causes of this, investigations needed, and how to tailor treatment to the individual if no pathology is found

Bleeding while taking hormone replacement therapy (HRT) is a relatively common problem. The majority of women with post-menopausal bleeding – on and off HRT – will have either no cause or a benign cause, but about 10% of women will have endometrial cancer. Post-menopausal bleeding is defined as unscheduled vaginal bleeding that occurs a year after the last natural menstrual period or any breakthrough bleeding on cyclical HRT or breakthrough bleeding after 6 months on continuous combined therapy when there has been established amenorrhoea. Practice nurses must be aware of the problem of bleeding on HRT and each individual needs to be assessed for pathology. If no pathology is found, treatment should be tailored to the individual to overcome the bleeding issues.

The aim of this article is to cover the causes of post-menopausal bleeding and irregular bleeding for women taking hormone replacement therapy (HRT) and how to manage it. Bleeding while on HRT is common and if once investigated no cause has been found, then the HRT prescribed may need to be changed.

Bleeding while taking HRT is a common problem and in the Women's Health Initiative trial 40% women were unblinded due to vaginal bleeding (Rossouw et al, 2002). It is estimated that 38% of women using sequential HRT and 41% of women on continuous combined HRT (CCT) attend clinics with bleeding (Hickey et al, 2009). Problems with bleeding do lead to the discontinuation of therapy and expensive and invasive tests to exclude cancer and pathology, and this may affect the acceptability of treatment for women.

The majority of women with post-menopausal bleeding on and off HRT will have either no cause or a benign cause, but about 10% of women will have endometrial cancer (Scottish Intercollegiate Guidelines Network [SIGN], 2002). Endometrial cancer accounts for 1 in 18 of all female cancers and is increasing due to multiple factors (Bray et al, 2005), the most prominent being obesity.

Register now to continue reading

Thank you for visiting Practice Nursing and reading some of our peer-reviewed resources for general practice nurses. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Limited access to clinical or professional articles

  • New content and clinical newsletter updates each month